Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a poised for growth in the oncology market, with a focus on treating LGSOC and pancreatic cancer and potential for their drug combination to become the new standard of care. Their drug VS-7375 has shown potential for maximal tumor regression and partnerships and expected peak sales further support their potential for success. Investors should keep an eye on upcoming data releases and trials, as well as competition in the market.

Bears say

Verastem is a late-stage development biopharmaceutical company focused on novel anticancer agents that inhibit critical signaling pathways in cancer, particularly through RAF/MEK and FAK inhibition, but its preliminary efficacy update for these drugs in 2H26 is expected to be limited and may only lead to a modest increase in stock price. Additionally, although darovonrasib and VS-7375 show strong potential in PDAC and NSCLC, there are limitations such as rash burden and GI toxicity which may hinder their success in combination therapies. Furthermore, as a clinical-stage company, Verastem faces a range of standard risks in the biopharmaceutical industry which could affect its development, regulatory approval, and commercial success.

Verastem (VSTM) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.